ABL Diagnostics (Euronext: ABLD) has invited shareholders to an Ordinary and Extraordinary General Meeting on September 17, 2026, to approve the transfer of its listing from the regulated market of Euronext Paris to the multilateral trading facility Euronext Growth Paris.

The meeting will also consider a proposed change to the company's corporate name. The event is scheduled for 11:00 am at the offices of De Gaulle Fleurance & Associés in Paris.

Meeting Details

The notice of meeting, published in the Bulletin des Annonces Légales Obligatoires (BALO) on August 12, 2026, outlines the agenda and proposed resolutions. Documents required under Article R.22-10-23 of the French Commercial Code are available for consultation on the company's website.

Corporate Profile

Headquartered in Woippy, ABL Diagnostics specializes in molecular biology tests. Its portfolio includes:

• Molecular polymerase chain reaction (PCR) detection via UltraGene
• Genotyping by DNA sequencing through DeepChek

The company markets its products globally through its own sales team and exclusive distributors. Customers include academic clinical pathology laboratories, private reference laboratories, and researchers.

Strategic Developments

Following the acquisition of TEXCELL’s operations, ABL Diagnostics is expanding into virology, biosafety testing, and biopharmaceutical development support. Since the second half of 2025, it has marketed products from sister company CDL Pharma under an intra-group strategy agreement.

ABL Diagnostics has announced a proposal to transfer the listing of its securities from the regulated market of Euronext Paris to the Euronext Growth Paris multilateral trading facility. The Board of Directors, meeting on August 6, 2026, decided to convene a shareholders’ meeting on September 17, 2026, to seek approval for this move. The transfer is designed to simplify operations and reduce regulatory constraints and costs associated with the regulated market, while keeping the company accessible to both professional and retail investors through the Euronext Growth platform.

The transfer requires shareholder approval at the general meeting and subsequent approval from Euronext Paris. If approved, the direct listing on Euronext Growth Paris will occur via an accelerated procedure for admitting existing shares to trading, without issuing new shares. AllInvest Securities will support the company as a listing sponsor. The company must meet eligibility conditions on the day of the transfer request, including a market capitalization of less than €1 billion and a minimum public distribution (free float) of €2.5 million.

Currently, the free float represents 5.99% of ABL Diagnostics’ share capital, valued at €2.41 million based on the closing price of €2.50 on August 6, 2026. This falls short of the €2.5 million minimum required for Euronext Growth. However, the company states that this condition will be met by the time of the transfer. Expanding the free float aligns with the company’s strategy since its 2021 merger, aiming for up to 30% of capital in free float subject to market conditions. Initiatives such as a liquidity contract and share sales by the reference shareholder have been undertaken to achieve this.

Regulatory and Operational Changes

The transfer brings several changes to reporting and governance requirements. ABL Diagnostics will publish an annual report within four months of the financial year-end, including financial statements, a reduced management report, and Statutory Auditors’ reports. Half-year reports will also be published within four months of the first half-year end, extending from the three-month period currently applicable on Euronext Paris. These half-year financial statements will no longer require audit by Statutory Auditors, though a review may be maintained.

The company will remain subject to Regulation (EU) No. 596/2014 on market abuse (MAR) for permanent market information, continuing to disseminate regulated and inside information via a professional broadcaster. Officers must still report trades, and insider lists must be maintained. Governance rules regarding Board parity and audit committees may no longer apply, depending on thresholds. Additionally, the “say on pay” regime for executive compensation policy approval will be removed.

Shareholder Rights and Timetable

General meeting formalities will be simplified, with preparatory documents published online on the notice date rather than twenty-one days prior. Minority shareholder protection remains ensured through mandatory public offer mechanisms if the 50% threshold of share capital or voting rights is crossed. For three years post-delisting, the company remains subject to the public offer regime for crossings of the 30% threshold under transitional provisions. Liquidity may change as Euronext Growth is an unregulated market, potentially affecting investor preference, though the existing liquidity contract with AllInvest Securities will continue.

What the Numbers Show

The current free float value of €2.41 million is just below the €2.5 million minimum requirement for Euronext Growth. This narrow gap indicates that only a modest increase in public shareholding or share price appreciation is needed to meet the eligibility criteria by the transfer date. The company’s assertion that the condition will be met suggests confidence in near-term liquidity initiatives or market movements. This minimal shortfall underscores that the primary driver for the transfer is structural cost reduction rather than addressing a significant liquidity deficit.